Supriya Lifescience Ltd Reports Rs 145.07 Cr Revenue and 35.6% EBITDA Margin in Q1 FY26

Supriya Lifescience Ltd., a cGMP-compliant company with a strong track record in APl manufacturing, has reported its unaudited financial results for the quarter ended June 30, 2025. The company witnessed a 9.7% year-over-year decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1 FY25. The EBITDA for Q1 FY26 stood at Rs 51.70 crore, with an EBITDA margin of 35.6%. The Profit After Tax (PAT) for Q1 FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1 FY25. The anaesthetic segment led the revenue in Q1, contributing 53% to the revenue. European markets now contribute 41% of the company's business revenue in Q1 FY26. The company has acquired three separate land parcels near different plants to support the future growth of various business segments.